Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01385280 · ClinicalTrials.gov registry record · NA
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
A NA study of Stage IV Breast Cancer and Stage IIIC Breast Cancer, sponsored by University of Arizona.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT01385280 is a NA study of Stage IV Breast Cancer and Stage IIIC Breast Cancer that has completed, run by University of Arizona. The registered enrollment target is 13 participants, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01385280, a NA study of Stage IV Breast Cancer and Stage IIIC Breast Cancer, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Estrogen can cause the growth of tumor cells. Hormone therapy using therapeutic estradiol may fight breast cancer by lowering the amount of estrogen the body makes. Though estradiol initially produces stimulation of ER+ cancer cells, both laboratory and some clinical experience indicate that it may have the opposite effect on such cells, once they have become resistant to estrogen deprivation. In laboratory models, there is death of the "resistant" population after estradiol treatment, followed by restoration of sensitivity of the remaining cells to estrogen deprivation, as with an aromatase inhibitor. Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving therapeutic estradiol together with exemestane may kill more tumor cells. PURPOSE: This clinical trial studies therapeutic estradiol and exemestane in treating post-menopausal patients with hormone receptor-positive metastatic breast cancer
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG exemestane
- BIOLOGICAL therapeutic estradiol
- OTHER enzyme-linked immunosorbent assay
Study Locations (1)
Arizona
- University of Arizona Cancer Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01385280
The ClinicalTrials.gov registry entry for NCT01385280 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (80% lower). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01385280 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT01385280 about?
NCT01385280 is a clinical study titled "Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer". RATIONALE: Estrogen can cause the growth of tumor cells. Hormone therapy using therapeutic estradiol may fight breast cancer by lowering the amount of estrogen the body makes. Though estradiol initially produces stimulation of ER+ cancer cells, both laboratory and some clinical experience indicate t...
What is the current status of trial NCT01385280?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2011-02. Estimated completion is 2013-10.
What conditions does trial NCT01385280 study?
This clinical trial studies the following conditions: Stage IV Breast Cancer, Stage IIIC Breast Cancer, Recurrent Breast Cancer, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor.
What interventions are being tested in trial NCT01385280?
The interventions under investigation include: laboratory biomarker analysis (OTHER), exemestane (DRUG), therapeutic estradiol (BIOLOGICAL), enzyme-linked immunosorbent assay (OTHER).
Who is sponsoring clinical trial NCT01385280?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01385280 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
RECRUITING · NA
-
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
ACTIVE NOT RECRUITING · NA
-
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
ACTIVE NOT RECRUITING · NA
-
Ask Questions (ASQ):Implementation of a Communication Intervention
COMPLETED · NA
-
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
COMPLETED · NA
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.